nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—chronic kidney failure—Calcium Acetate—osteoporosis	0.345	0.416	CpDpCtD
Deferoxamine—chronic kidney failure—Calcitriol—osteoporosis	0.261	0.315	CpDpCtD
Deferoxamine—chronic kidney failure—Cholecalciferol—osteoporosis	0.222	0.268	CpDpCtD
Deferoxamine—XDH—Purine catabolism—PNP—osteoporosis	0.0104	0.284	CbGpPWpGaD
Deferoxamine—XDH—Purine metabolism—ATIC—osteoporosis	0.004	0.109	CbGpPWpGaD
Deferoxamine—XDH—Purine metabolism—PNP—osteoporosis	0.004	0.109	CbGpPWpGaD
Deferoxamine—XDH—Purine catabolism—GPX1—osteoporosis	0.00295	0.0803	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—PNP—osteoporosis	0.00201	0.0548	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—ATIC—osteoporosis	0.00201	0.0548	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—PRDX3—osteoporosis	0.002	0.0544	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—SOD2—osteoporosis	0.00128	0.035	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—GPX1—osteoporosis	0.00122	0.0334	CbGpPWpGaD
Deferoxamine—XDH—Purine metabolism—GPX1—osteoporosis	0.00113	0.0309	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—GPX1—osteoporosis	0.00057	0.0155	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SOD2—osteoporosis	0.000543	0.0148	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—GPX1—osteoporosis	0.000518	0.0141	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000478	0.013	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—IL1B—osteoporosis	0.000284	0.00772	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—FDPS—osteoporosis	0.000211	0.00574	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PKM—osteoporosis	0.000211	0.00574	CbGpPWpGaD
Deferoxamine—Immune system disorder—Zoledronate—osteoporosis	0.000209	0.00155	CcSEcCtD
Deferoxamine—Mediastinal disorder—Zoledronate—osteoporosis	0.000209	0.00155	CcSEcCtD
Deferoxamine—Eye disorder—Conjugated Estrogens—osteoporosis	0.000208	0.00155	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Estropipate—osteoporosis	0.000207	0.00154	CcSEcCtD
Deferoxamine—Arrhythmia—Zoledronate—osteoporosis	0.000207	0.00154	CcSEcCtD
Deferoxamine—Paraesthesia—Ibandronate—osteoporosis	0.000206	0.00153	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—TNF—osteoporosis	0.000206	0.0056	CbGpPWpGaD
Deferoxamine—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.000205	0.00152	CcSEcCtD
Deferoxamine—Pain—Estropipate—osteoporosis	0.000205	0.00152	CcSEcCtD
Deferoxamine—Hypersensitivity—Etidronic acid—osteoporosis	0.000204	0.00152	CcSEcCtD
Deferoxamine—Angiopathy—Conjugated Estrogens—osteoporosis	0.000202	0.0015	CcSEcCtD
Deferoxamine—Pain—Alendronate—osteoporosis	0.000202	0.0015	CcSEcCtD
Deferoxamine—Angioedema—Pamidronate—osteoporosis	0.000202	0.0015	CcSEcCtD
Deferoxamine—Erythema—Zoledronate—osteoporosis	0.000202	0.0015	CcSEcCtD
Deferoxamine—Immune system disorder—Conjugated Estrogens—osteoporosis	0.000201	0.0015	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000201	0.0015	CcSEcCtD
Deferoxamine—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000201	0.00149	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Raloxifene—osteoporosis	0.0002	0.00149	CcSEcCtD
Deferoxamine—XDH—Metabolism—GPD2—osteoporosis	0.0002	0.00544	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PGLS—osteoporosis	0.0002	0.00544	CbGpPWpGaD
Deferoxamine—Arrhythmia—Conjugated Estrogens—osteoporosis	0.000199	0.00148	CcSEcCtD
Deferoxamine—Infestation—Estradiol—osteoporosis	0.000199	0.00148	CcSEcCtD
Deferoxamine—Infestation NOS—Estradiol—osteoporosis	0.000199	0.00148	CcSEcCtD
Deferoxamine—Pain—Raloxifene—osteoporosis	0.000199	0.00148	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000198	0.00147	CcSEcCtD
Deferoxamine—Arthralgia—Risedronate—osteoporosis	0.000198	0.00147	CcSEcCtD
Deferoxamine—Myalgia—Risedronate—osteoporosis	0.000198	0.00147	CcSEcCtD
Deferoxamine—Leukopenia—Pamidronate—osteoporosis	0.000197	0.00147	CcSEcCtD
Deferoxamine—Pain—Ibandronate—osteoporosis	0.000197	0.00146	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000196	0.00146	CcSEcCtD
Deferoxamine—Pruritus—Etidronic acid—osteoporosis	0.000196	0.00146	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Estropipate—osteoporosis	0.000196	0.00146	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Estradiol—osteoporosis	0.000195	0.00145	CcSEcCtD
Deferoxamine—Oedema—Ethinyl Estradiol—osteoporosis	0.000194	0.00144	CcSEcCtD
Deferoxamine—Erythema—Conjugated Estrogens—osteoporosis	0.000194	0.00144	CcSEcCtD
Deferoxamine—Muscle spasms—Zoledronate—osteoporosis	0.000194	0.00144	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Alendronate—osteoporosis	0.000193	0.00143	CcSEcCtD
Deferoxamine—Infection—Ethinyl Estradiol—osteoporosis	0.000193	0.00143	CcSEcCtD
Deferoxamine—Pain—Calcitriol—osteoporosis	0.000192	0.00143	CcSEcCtD
Deferoxamine—Convulsion—Pamidronate—osteoporosis	0.000191	0.00142	CcSEcCtD
Deferoxamine—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000191	0.00142	CcSEcCtD
Deferoxamine—Urticaria—Estropipate—osteoporosis	0.00019	0.00141	CcSEcCtD
Deferoxamine—Vision blurred—Zoledronate—osteoporosis	0.00019	0.00141	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Raloxifene—osteoporosis	0.00019	0.00141	CcSEcCtD
Deferoxamine—Diarrhoea—Etidronic acid—osteoporosis	0.00019	0.00141	CcSEcCtD
Deferoxamine—Body temperature increased—Estropipate—osteoporosis	0.000189	0.00141	CcSEcCtD
Deferoxamine—Abdominal pain—Estropipate—osteoporosis	0.000189	0.00141	CcSEcCtD
Deferoxamine—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000189	0.0014	CcSEcCtD
Deferoxamine—Infection—Risedronate—osteoporosis	0.000188	0.0014	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Ibandronate—osteoporosis	0.000188	0.0014	CcSEcCtD
Deferoxamine—Myalgia—Pamidronate—osteoporosis	0.000188	0.0014	CcSEcCtD
Deferoxamine—Arthralgia—Pamidronate—osteoporosis	0.000188	0.0014	CcSEcCtD
Deferoxamine—Urticaria—Alendronate—osteoporosis	0.000188	0.00139	CcSEcCtD
Deferoxamine—Abdominal pain—Alendronate—osteoporosis	0.000187	0.00139	CcSEcCtD
Deferoxamine—Body temperature increased—Alendronate—osteoporosis	0.000187	0.00139	CcSEcCtD
Deferoxamine—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000187	0.00139	CcSEcCtD
Deferoxamine—Shock—Risedronate—osteoporosis	0.000186	0.00138	CcSEcCtD
Deferoxamine—Nervous system disorder—Risedronate—osteoporosis	0.000186	0.00138	CcSEcCtD
Deferoxamine—Angioedema—Zoledronate—osteoporosis	0.000184	0.00137	CcSEcCtD
Deferoxamine—Skin disorder—Risedronate—osteoporosis	0.000184	0.00137	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Calcitriol—osteoporosis	0.000184	0.00137	CcSEcCtD
Deferoxamine—Body temperature increased—Raloxifene—osteoporosis	0.000184	0.00136	CcSEcCtD
Deferoxamine—Abdominal pain—Raloxifene—osteoporosis	0.000184	0.00136	CcSEcCtD
Deferoxamine—Vision blurred—Conjugated Estrogens—osteoporosis	0.000183	0.00136	CcSEcCtD
Deferoxamine—XDH—Metabolism—ATIC—osteoporosis	0.000183	0.00498	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PNP—osteoporosis	0.000183	0.00498	CbGpPWpGaD
Deferoxamine—Urticaria—Ibandronate—osteoporosis	0.000183	0.00136	CcSEcCtD
Deferoxamine—Abdominal pain—Ibandronate—osteoporosis	0.000182	0.00135	CcSEcCtD
Deferoxamine—Body temperature increased—Ibandronate—osteoporosis	0.000182	0.00135	CcSEcCtD
Deferoxamine—Leukopenia—Zoledronate—osteoporosis	0.00018	0.00134	CcSEcCtD
Deferoxamine—Anaphylactic shock—Pamidronate—osteoporosis	0.00018	0.00134	CcSEcCtD
Deferoxamine—Oedema—Pamidronate—osteoporosis	0.00018	0.00134	CcSEcCtD
Deferoxamine—Infection—Pamidronate—osteoporosis	0.000179	0.00133	CcSEcCtD
Deferoxamine—Urticaria—Calcitriol—osteoporosis	0.000179	0.00133	CcSEcCtD
Deferoxamine—Abdominal pain—Calcitriol—osteoporosis	0.000178	0.00132	CcSEcCtD
Deferoxamine—Body temperature increased—Calcitriol—osteoporosis	0.000178	0.00132	CcSEcCtD
Deferoxamine—Angioedema—Conjugated Estrogens—osteoporosis	0.000177	0.00132	CcSEcCtD
Deferoxamine—Shock—Pamidronate—osteoporosis	0.000177	0.00132	CcSEcCtD
Deferoxamine—Hypersensitivity—Estropipate—osteoporosis	0.000177	0.00131	CcSEcCtD
Deferoxamine—Nervous system disorder—Pamidronate—osteoporosis	0.000177	0.00131	CcSEcCtD
Deferoxamine—Thrombocytopenia—Pamidronate—osteoporosis	0.000176	0.00131	CcSEcCtD
Deferoxamine—Urinary tract disorder—Estradiol—osteoporosis	0.000176	0.00131	CcSEcCtD
Deferoxamine—Vomiting—Etidronic acid—osteoporosis	0.000176	0.00131	CcSEcCtD
Deferoxamine—Tachycardia—Pamidronate—osteoporosis	0.000176	0.00131	CcSEcCtD
Deferoxamine—Connective tissue disorder—Estradiol—osteoporosis	0.000175	0.0013	CcSEcCtD
Deferoxamine—Urethral disorder—Estradiol—osteoporosis	0.000175	0.0013	CcSEcCtD
Deferoxamine—Convulsion—Zoledronate—osteoporosis	0.000175	0.0013	CcSEcCtD
Deferoxamine—Hypersensitivity—Alendronate—osteoporosis	0.000174	0.00129	CcSEcCtD
Deferoxamine—Headache—Etidronic acid—osteoporosis	0.000174	0.00129	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000173	0.00128	CcSEcCtD
Deferoxamine—Visual impairment—Estradiol—osteoporosis	0.000172	0.00128	CcSEcCtD
Deferoxamine—Arthralgia—Zoledronate—osteoporosis	0.000172	0.00127	CcSEcCtD
Deferoxamine—Myalgia—Zoledronate—osteoporosis	0.000172	0.00127	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00017	0.00127	CcSEcCtD
Deferoxamine—Paraesthesia—Risedronate—osteoporosis	0.00017	0.00126	CcSEcCtD
Deferoxamine—Pruritus—Estropipate—osteoporosis	0.00017	0.00126	CcSEcCtD
Deferoxamine—Hypersensitivity—Ibandronate—osteoporosis	0.000169	0.00126	CcSEcCtD
Deferoxamine—Dyspnoea—Risedronate—osteoporosis	0.000169	0.00125	CcSEcCtD
Deferoxamine—Hypotension—Pamidronate—osteoporosis	0.000168	0.00125	CcSEcCtD
Deferoxamine—Convulsion—Conjugated Estrogens—osteoporosis	0.000168	0.00125	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000168	0.00125	CcSEcCtD
Deferoxamine—Pruritus—Alendronate—osteoporosis	0.000167	0.00124	CcSEcCtD
Deferoxamine—Eye disorder—Estradiol—osteoporosis	0.000167	0.00124	CcSEcCtD
Deferoxamine—Tinnitus—Estradiol—osteoporosis	0.000166	0.00124	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—IL6—osteoporosis	0.000166	0.00452	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Calcitriol—osteoporosis	0.000166	0.00123	CcSEcCtD
Deferoxamine—Arthralgia—Conjugated Estrogens—osteoporosis	0.000165	0.00123	CcSEcCtD
Deferoxamine—Myalgia—Conjugated Estrogens—osteoporosis	0.000165	0.00123	CcSEcCtD
Deferoxamine—Nausea—Etidronic acid—osteoporosis	0.000165	0.00122	CcSEcCtD
Deferoxamine—Anaphylactic shock—Zoledronate—osteoporosis	0.000164	0.00122	CcSEcCtD
Deferoxamine—Oedema—Zoledronate—osteoporosis	0.000164	0.00122	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000164	0.00122	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000164	0.00122	CcSEcCtD
Deferoxamine—Diarrhoea—Estropipate—osteoporosis	0.000164	0.00122	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Risedronate—osteoporosis	0.000164	0.00122	CcSEcCtD
Deferoxamine—Infection—Zoledronate—osteoporosis	0.000163	0.00121	CcSEcCtD
Deferoxamine—Pruritus—Ibandronate—osteoporosis	0.000163	0.00121	CcSEcCtD
Deferoxamine—Pain—Risedronate—osteoporosis	0.000162	0.0012	CcSEcCtD
Deferoxamine—Angiopathy—Estradiol—osteoporosis	0.000162	0.0012	CcSEcCtD
Deferoxamine—Shock—Zoledronate—osteoporosis	0.000162	0.0012	CcSEcCtD
Deferoxamine—Paraesthesia—Pamidronate—osteoporosis	0.000162	0.0012	CcSEcCtD
Deferoxamine—Diarrhoea—Alendronate—osteoporosis	0.000162	0.0012	CcSEcCtD
Deferoxamine—Nervous system disorder—Zoledronate—osteoporosis	0.000161	0.0012	CcSEcCtD
Deferoxamine—Immune system disorder—Estradiol—osteoporosis	0.000161	0.0012	CcSEcCtD
Deferoxamine—Thrombocytopenia—Zoledronate—osteoporosis	0.000161	0.0012	CcSEcCtD
Deferoxamine—Mediastinal disorder—Estradiol—osteoporosis	0.000161	0.00119	CcSEcCtD
Deferoxamine—Dyspnoea—Pamidronate—osteoporosis	0.000161	0.00119	CcSEcCtD
Deferoxamine—Tachycardia—Zoledronate—osteoporosis	0.000161	0.00119	CcSEcCtD
Deferoxamine—Skin disorder—Zoledronate—osteoporosis	0.00016	0.00119	CcSEcCtD
Deferoxamine—Pruritus—Calcitriol—osteoporosis	0.000159	0.00118	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000159	0.00118	CcSEcCtD
Deferoxamine—Diarrhoea—Raloxifene—osteoporosis	0.000159	0.00118	CcSEcCtD
Deferoxamine—Dizziness—Estropipate—osteoporosis	0.000158	0.00118	CcSEcCtD
Deferoxamine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000158	0.00118	CcSEcCtD
Deferoxamine—Oedema—Conjugated Estrogens—osteoporosis	0.000158	0.00118	CcSEcCtD
Deferoxamine—Infection—Conjugated Estrogens—osteoporosis	0.000157	0.00117	CcSEcCtD
Deferoxamine—Diarrhoea—Ibandronate—osteoporosis	0.000157	0.00117	CcSEcCtD
Deferoxamine—Dizziness—Alendronate—osteoporosis	0.000156	0.00116	CcSEcCtD
Deferoxamine—Shock—Conjugated Estrogens—osteoporosis	0.000156	0.00116	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000155	0.00116	CcSEcCtD
Deferoxamine—XDH—Metabolism—OXCT1—osteoporosis	0.000155	0.00423	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CA2—osteoporosis	0.000155	0.00423	CbGpPWpGaD
Deferoxamine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000155	0.00115	CcSEcCtD
Deferoxamine—Erythema—Estradiol—osteoporosis	0.000155	0.00115	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Risedronate—osteoporosis	0.000155	0.00115	CcSEcCtD
Deferoxamine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000155	0.00115	CcSEcCtD
Deferoxamine—Urticaria—Ethinyl Estradiol—osteoporosis	0.000154	0.00115	CcSEcCtD
Deferoxamine—Pain—Pamidronate—osteoporosis	0.000154	0.00114	CcSEcCtD
Deferoxamine—Diarrhoea—Calcitriol—osteoporosis	0.000154	0.00114	CcSEcCtD
Deferoxamine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000154	0.00114	CcSEcCtD
Deferoxamine—Hypotension—Zoledronate—osteoporosis	0.000154	0.00114	CcSEcCtD
Deferoxamine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000154	0.00114	CcSEcCtD
Deferoxamine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000154	0.00114	CcSEcCtD
Deferoxamine—Dizziness—Raloxifene—osteoporosis	0.000154	0.00114	CcSEcCtD
Deferoxamine—Vomiting—Estropipate—osteoporosis	0.000152	0.00113	CcSEcCtD
Deferoxamine—Dizziness—Ibandronate—osteoporosis	0.000152	0.00113	CcSEcCtD
Deferoxamine—XDH—Metabolism—MGLL—osteoporosis	0.000151	0.00413	CbGpPWpGaD
Deferoxamine—Urticaria—Risedronate—osteoporosis	0.00015	0.00112	CcSEcCtD
Deferoxamine—Headache—Estropipate—osteoporosis	0.00015	0.00112	CcSEcCtD
Deferoxamine—Vomiting—Alendronate—osteoporosis	0.00015	0.00112	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00015	0.00111	CcSEcCtD
Deferoxamine—Abdominal pain—Risedronate—osteoporosis	0.00015	0.00111	CcSEcCtD
Deferoxamine—Body temperature increased—Risedronate—osteoporosis	0.00015	0.00111	CcSEcCtD
Deferoxamine—Muscle spasms—Estradiol—osteoporosis	0.000149	0.00111	CcSEcCtD
Deferoxamine—Hypotension—Conjugated Estrogens—osteoporosis	0.000148	0.0011	CcSEcCtD
Deferoxamine—Headache—Alendronate—osteoporosis	0.000148	0.0011	CcSEcCtD
Deferoxamine—Paraesthesia—Zoledronate—osteoporosis	0.000148	0.0011	CcSEcCtD
Deferoxamine—Vomiting—Raloxifene—osteoporosis	0.000148	0.0011	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Pamidronate—osteoporosis	0.000147	0.00109	CcSEcCtD
Deferoxamine—Dyspnoea—Zoledronate—osteoporosis	0.000147	0.00109	CcSEcCtD
Deferoxamine—Vomiting—Ibandronate—osteoporosis	0.000146	0.00109	CcSEcCtD
Deferoxamine—Headache—Raloxifene—osteoporosis	0.000145	0.00108	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000144	0.00107	CcSEcCtD
Deferoxamine—Headache—Ibandronate—osteoporosis	0.000144	0.00107	CcSEcCtD
Deferoxamine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000143	0.00106	CcSEcCtD
Deferoxamine—Vomiting—Calcitriol—osteoporosis	0.000143	0.00106	CcSEcCtD
Deferoxamine—Nausea—Estropipate—osteoporosis	0.000142	0.00106	CcSEcCtD
Deferoxamine—Abdominal pain—Pamidronate—osteoporosis	0.000142	0.00106	CcSEcCtD
Deferoxamine—Body temperature increased—Pamidronate—osteoporosis	0.000142	0.00106	CcSEcCtD
Deferoxamine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000142	0.00106	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000142	0.00106	CcSEcCtD
Deferoxamine—Angioedema—Estradiol—osteoporosis	0.000142	0.00105	CcSEcCtD
Deferoxamine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000141	0.00105	CcSEcCtD
Deferoxamine—Headache—Calcitriol—osteoporosis	0.000141	0.00105	CcSEcCtD
Deferoxamine—Pain—Zoledronate—osteoporosis	0.000141	0.00105	CcSEcCtD
Deferoxamine—Nausea—Alendronate—osteoporosis	0.00014	0.00104	CcSEcCtD
Deferoxamine—Hypersensitivity—Risedronate—osteoporosis	0.00014	0.00104	CcSEcCtD
Deferoxamine—Nausea—Raloxifene—osteoporosis	0.000138	0.00102	CcSEcCtD
Deferoxamine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000137	0.00102	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000137	0.00102	CcSEcCtD
Deferoxamine—Nausea—Ibandronate—osteoporosis	0.000137	0.00101	CcSEcCtD
Deferoxamine—Pain—Conjugated Estrogens—osteoporosis	0.000135	0.00101	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Zoledronate—osteoporosis	0.000134	0.000999	CcSEcCtD
Deferoxamine—Pruritus—Risedronate—osteoporosis	0.000134	0.000996	CcSEcCtD
Deferoxamine—Nausea—Calcitriol—osteoporosis	0.000134	0.000993	CcSEcCtD
Deferoxamine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000133	0.000988	CcSEcCtD
Deferoxamine—Hypersensitivity—Pamidronate—osteoporosis	0.000133	0.000986	CcSEcCtD
Deferoxamine—Arthralgia—Estradiol—osteoporosis	0.000132	0.000982	CcSEcCtD
Deferoxamine—Myalgia—Estradiol—osteoporosis	0.000132	0.000982	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000131	0.000976	CcSEcCtD
Deferoxamine—Urticaria—Zoledronate—osteoporosis	0.000131	0.000971	CcSEcCtD
Deferoxamine—Body temperature increased—Zoledronate—osteoporosis	0.00013	0.000966	CcSEcCtD
Deferoxamine—Abdominal pain—Zoledronate—osteoporosis	0.00013	0.000966	CcSEcCtD
Deferoxamine—Diarrhoea—Risedronate—osteoporosis	0.00013	0.000963	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000129	0.000962	CcSEcCtD
Deferoxamine—XDH—Metabolism—IDH2—osteoporosis	0.000129	0.00351	CbGpPWpGaD
Deferoxamine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000128	0.000955	CcSEcCtD
Deferoxamine—Pruritus—Pamidronate—osteoporosis	0.000127	0.000947	CcSEcCtD
Deferoxamine—Anaphylactic shock—Estradiol—osteoporosis	0.000127	0.000942	CcSEcCtD
Deferoxamine—Oedema—Estradiol—osteoporosis	0.000127	0.000942	CcSEcCtD
Deferoxamine—Infection—Estradiol—osteoporosis	0.000126	0.000936	CcSEcCtD
Deferoxamine—Urticaria—Conjugated Estrogens—osteoporosis	0.000126	0.000935	CcSEcCtD
Deferoxamine—Dizziness—Risedronate—osteoporosis	0.000125	0.000931	CcSEcCtD
Deferoxamine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000125	0.00093	CcSEcCtD
Deferoxamine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000125	0.00093	CcSEcCtD
Deferoxamine—Shock—Estradiol—osteoporosis	0.000125	0.000927	CcSEcCtD
Deferoxamine—Nervous system disorder—Estradiol—osteoporosis	0.000124	0.000924	CcSEcCtD
Deferoxamine—Tachycardia—Estradiol—osteoporosis	0.000124	0.000919	CcSEcCtD
Deferoxamine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000124	0.000918	CcSEcCtD
Deferoxamine—Diarrhoea—Pamidronate—osteoporosis	0.000123	0.000915	CcSEcCtD
Deferoxamine—Skin disorder—Estradiol—osteoporosis	0.000123	0.000915	CcSEcCtD
Deferoxamine—Headache—Ethinyl Estradiol—osteoporosis	0.000122	0.000904	CcSEcCtD
Deferoxamine—Hypersensitivity—Zoledronate—osteoporosis	0.000121	0.0009	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP27A1—osteoporosis	0.000121	0.0033	CbGpPWpGaD
Deferoxamine—Vomiting—Risedronate—osteoporosis	0.00012	0.000895	CcSEcCtD
Deferoxamine—Dizziness—Pamidronate—osteoporosis	0.000119	0.000885	CcSEcCtD
Deferoxamine—Headache—Risedronate—osteoporosis	0.000119	0.000882	CcSEcCtD
Deferoxamine—XDH—Metabolism—ACP5—osteoporosis	0.000118	0.00321	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000117	0.000867	CcSEcCtD
Deferoxamine—Pruritus—Zoledronate—osteoporosis	0.000116	0.000865	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000115	0.000858	CcSEcCtD
Deferoxamine—Nausea—Ethinyl Estradiol—osteoporosis	0.000115	0.000857	CcSEcCtD
Deferoxamine—Vomiting—Pamidronate—osteoporosis	0.000114	0.000851	CcSEcCtD
Deferoxamine—Paraesthesia—Estradiol—osteoporosis	0.000114	0.000846	CcSEcCtD
Deferoxamine—Dyspnoea—Estradiol—osteoporosis	0.000113	0.00084	CcSEcCtD
Deferoxamine—Headache—Pamidronate—osteoporosis	0.000113	0.000838	CcSEcCtD
Deferoxamine—Diarrhoea—Zoledronate—osteoporosis	0.000113	0.000836	CcSEcCtD
Deferoxamine—Nausea—Risedronate—osteoporosis	0.000113	0.000836	CcSEcCtD
Deferoxamine—Pruritus—Conjugated Estrogens—osteoporosis	0.000112	0.000833	CcSEcCtD
Deferoxamine—XDH—Metabolism—TPI1—osteoporosis	0.000109	0.00298	CbGpPWpGaD
Deferoxamine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000109	0.000813	CcSEcCtD
Deferoxamine—Dizziness—Zoledronate—osteoporosis	0.000109	0.000808	CcSEcCtD
Deferoxamine—Pain—Estradiol—osteoporosis	0.000108	0.000805	CcSEcCtD
Deferoxamine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000108	0.000805	CcSEcCtD
Deferoxamine—Nausea—Pamidronate—osteoporosis	0.000107	0.000795	CcSEcCtD
Deferoxamine—Dizziness—Conjugated Estrogens—osteoporosis	0.000105	0.000778	CcSEcCtD
Deferoxamine—Vomiting—Zoledronate—osteoporosis	0.000105	0.000777	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Estradiol—osteoporosis	0.000104	0.00077	CcSEcCtD
Deferoxamine—Headache—Zoledronate—osteoporosis	0.000103	0.000766	CcSEcCtD
Deferoxamine—XDH—Metabolism—P4HB—osteoporosis	0.000103	0.0028	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GAPDH—osteoporosis	0.000101	0.00275	CbGpPWpGaD
Deferoxamine—Vomiting—Conjugated Estrogens—osteoporosis	0.000101	0.000748	CcSEcCtD
Deferoxamine—Urticaria—Estradiol—osteoporosis	0.000101	0.000748	CcSEcCtD
Deferoxamine—Body temperature increased—Estradiol—osteoporosis	0.0001	0.000745	CcSEcCtD
Deferoxamine—Abdominal pain—Estradiol—osteoporosis	0.0001	0.000745	CcSEcCtD
Deferoxamine—Headache—Conjugated Estrogens—osteoporosis	9.92e-05	0.000737	CcSEcCtD
Deferoxamine—XDH—Metabolism—RAP1A—osteoporosis	9.84e-05	0.00268	CbGpPWpGaD
Deferoxamine—Nausea—Zoledronate—osteoporosis	9.77e-05	0.000726	CcSEcCtD
Deferoxamine—Nausea—Conjugated Estrogens—osteoporosis	9.41e-05	0.000699	CcSEcCtD
Deferoxamine—Hypersensitivity—Estradiol—osteoporosis	9.34e-05	0.000694	CcSEcCtD
Deferoxamine—Pruritus—Estradiol—osteoporosis	8.97e-05	0.000666	CcSEcCtD
Deferoxamine—Diarrhoea—Estradiol—osteoporosis	8.67e-05	0.000644	CcSEcCtD
Deferoxamine—Dizziness—Estradiol—osteoporosis	8.38e-05	0.000623	CcSEcCtD
Deferoxamine—Vomiting—Estradiol—osteoporosis	8.06e-05	0.000599	CcSEcCtD
Deferoxamine—XDH—Metabolism—ENO1—osteoporosis	7.96e-05	0.00217	CbGpPWpGaD
Deferoxamine—Headache—Estradiol—osteoporosis	7.94e-05	0.00059	CcSEcCtD
Deferoxamine—XDH—Metabolism—PSMA2—osteoporosis	7.84e-05	0.00214	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PSMA5—osteoporosis	7.84e-05	0.00214	CbGpPWpGaD
Deferoxamine—Nausea—Estradiol—osteoporosis	7.53e-05	0.000559	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP19A1—osteoporosis	6.36e-05	0.00173	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ADCY5—osteoporosis	5.2e-05	0.00142	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GPX1—osteoporosis	5.18e-05	0.00141	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—MTHFR—osteoporosis	4.78e-05	0.0013	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—POMC—osteoporosis	3.82e-05	0.00104	CbGpPWpGaD
